MDXG logo

MiMedx Group Inc (MDXG)

$3.18

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MDXG

Market cap

$464043379

EPS

-0.13

P/E ratio

--

Price to sales

1.92

Dividend yield

--

Beta

1.169334

Price on MDXG

Previous close

$3.18

Today's open

$3.18

Day's range

$3.11 - $3.23

52 week range

$3.03 - $7.51

Profile about MDXG

CEO

Joseph H. Capper

Employees

808

Headquarters

Marietta, GA

Exchange

NASDAQ Capital Market

Shares outstanding

145925591

Issue type

Common Stock

MDXG industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MDXG

MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles

MiMedx Group NASDAQ: MDXG is counting on growth in its surgical business and its pending acquisition of Sanara MedTech to help offset a difficult year for its wound care franchise, Chief Financial Officer Doug Rice said at the Canaccord Genuity MedTech and Diagnostics Conference.

news source

MarketBeat • Nov 16, 2026

news preview

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

news source

GlobeNewsWire • Nov 6, 2026

news preview

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx Group NASDAQ: MDXG reported third-quarter net sales of $62 million, down 45% from a year earlier, as continued disruption in the wound care market offset growth in its surgical business. The company said surgical revenue rose 9% year over year to $40 million, while wound care revenue declined 71% to $22 million following Medicare reimbursement changes that took effect at the beginning of 2026.

news source

MarketBeat • Oct 29, 2026

news preview

MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 28, 2026

news preview

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter During Quarter Today Announced Patent License Agreement, Underscoring Strength of IP Portfolio Management to Host Conference Call Today, October 28, 2026, at 4:30 PM ET MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced operating and financial results for the third quarter of 2026.

news source

GlobeNewsWire • Oct 28, 2026

news preview

MIMEDX Announces $25 Million Patent License Agreement

MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of MIMEDX's patents.

news source

GlobeNewsWire • Oct 28, 2026

news preview

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

news source

GlobeNewsWire • Oct 14, 2026

news preview

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product

news source

GlobeNewsWire • Sep 23, 2026

news preview

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this consi.

news source

Business Wire • Sep 10, 2026

news preview

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Jul 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in MiMedx Group Inc

Open an M1 investment account to buy and sell MiMedx Group Inc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MDXG on M1